Cargando…
Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund
BACKGROUND: The NHS Cancer Drugs Fund (CDF) was established in 2010 to reduce delays and improve access to cancer drugs, including those that had been previously appraised but not approved by NICE (National Institute for Health and Care Excellence). After 1.3 billion GBP expenditure, a UK parliament...
Autores principales: | Aggarwal, A., Fojo, T., Chamberlain, C., Davis, C., Sullivan, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834015/ https://www.ncbi.nlm.nih.gov/pubmed/28453615 http://dx.doi.org/10.1093/annonc/mdx110 |
Ejemplares similares
-
Professional experiences of accessing cancer drugs in the NHS: the introduction of the Cancer Drugs Fund, the individual versus the population
por: Chamberlain, Charlotte, et al.
Publicado: (2014) -
NHS Volunteer Responders Scheme
por: Patel, S.
Publicado: (2021) -
Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada
por: Verma, S., et al.
Publicado: (2007) -
The Role of Funding and Policies on Innovation in Cancer Drug Development
por: Kanavos, P, et al.
Publicado: (2010) -
Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales
por: Chamberlain, C, et al.
Publicado: (2014)